Ozempic has been difficult to find for much of the past two years because demand has massively outpaced manufacturing capacity. Between January 2021 and December 2023, semaglutide prescriptions in the United States surged by 442%, jumping from roughly 472,000 monthly fills to over 2.5 million. No pharmaceutical supply chain was built to absorb that kind of growth, and the result has been rolling shortages that left pharmacies unable to fill prescriptions for months at a time.
The good news: the situation is improving. As of early 2025, semaglutide no longer appears on the FDA’s official drug shortage list. But depending on your location, your dose strength, and your pharmacy’s distribution agreements, you may still run into gaps. Here’s why the shortage happened, what’s being done about it, and what it means if you’re trying to stay on your medication.
How Demand Overwhelmed Supply
Ozempic was approved for type 2 diabetes, but its reputation as a weight loss drug spread fast. By the peak in August 2023, nearly 2 million semaglutide prescriptions were being filled in a single month, a 392% increase from just two and a half years earlier. Ozempic accounted for more than 70% of all semaglutide fills during that period.
It’s worth noting that the weight loss narrative, while real, is sometimes overstated as a cause of the shortage. An analysis of more than 4 million GLP-1 prescriptions written between 2018 and late 2024 found that about 84% were for patients with diabetes, while roughly 16% were for weight loss alone. The bigger driver was simply that more people with diabetes were being prescribed these newer medications as clinical evidence mounted in their favor. The weight loss demand added pressure on top of an already strained system, but the core problem was that millions of new patients across both categories entered the pipeline faster than manufacturing could scale.
Why Manufacturing Can’t Just Speed Up
Making Ozempic isn’t like bottling a soft drink. The process involves producing the active ingredient through biological fermentation, then filling it into precision injection pens at exact concentrations. Both steps are complex, and the second one, called “fill-finish,” became a major bottleneck.
Novo Nordisk, the company behind Ozempic, has described removing bottlenecks in its existing supply chain as a top priority. The company is investing more than 80 billion Danish kroner (roughly $11 billion) to expand production of the active ingredient alone, including a massive new 170,000-square-meter manufacturing facility in Kalundborg, Denmark. But pharmaceutical plants take years to build, validate, and bring online.
To move faster, Novo Nordisk’s parent company acquired the contract manufacturer Catalent in a $16.5 billion deal. Three Catalent fill-finish sites in Italy, Belgium, and Indiana were then transferred to Novo Nordisk for $11 billion, specifically to boost the number of injection pens coming off production lines. That added capacity began contributing to supply in 2026. The company is also consolidating its older insulin portfolio to free up manufacturing lines for newer drugs like Ozempic and Wegovy, and shifting toward reusable pen devices and once-weekly formulations that use production resources more efficiently.
What Happens When You Can’t Get Your Dose
For people with type 2 diabetes, an interrupted supply isn’t just inconvenient. It can mean losing the blood sugar control that took months to build. For those using semaglutide for weight management, the data on stopping treatment is sobering. In one major clinical trial, patients who lost an average of 10.6% of their body weight on semaglutide regained about 6.9% after being switched to a placebo, while those who stayed on the drug continued losing weight. A longer-term study found that after stopping semaglutide following 68 weeks of treatment, participants regained about 11.6 percentage points of the weight they had lost over the following year. Most of the improvements in heart and metabolic health that came with treatment also reversed toward their starting levels.
This rebound effect is why shortages hit patients so hard. Missing a week or two is manageable, but a months-long gap can essentially reset progress.
Options If Your Pharmacy Is Out
If your specific dose or brand isn’t available, your doctor may switch you to another GLP-1 medication based on what’s in stock. Both U.S. and European medical authorities have encouraged clinicians to use their judgment in transitioning patients to suitable alternatives during shortages rather than leaving them without treatment entirely. The key is not to try to manage a switch on your own, since different GLP-1 drugs have different dosing schedules and titration steps.
Some patients have turned to compounded versions of semaglutide, which are custom-mixed by specialty pharmacies. This carries real risk. The FDA has issued alerts about dosing errors with compounded semaglutide injectables, some serious enough to require hospitalization. The problems include compounders using salt forms of semaglutide (like semaglutide sodium or semaglutide acetate) that are chemically different from what’s in the approved drug. Some add extra ingredients like vitamin B-12, L-carnitine, or NAD whose safety in combination with semaglutide has never been tested. Overdose-related adverse events reported to the FDA include severe nausea and vomiting, fainting, acute pancreatitis, and gallstones. Concentration differences between compounded vials and the standard pen also create confusion that leads to dosing mistakes.
Where Things Stand Now
The formal shortage has eased. Semaglutide is no longer on the FDA’s drug shortage list, and manufacturing expansions are starting to deliver more supply. But “no longer in shortage” at the federal level doesn’t always match the experience at your local pharmacy. Distribution is uneven, and certain dose strengths may still be harder to find in some regions. If you’re having trouble filling a prescription, calling multiple pharmacies or asking your doctor’s office to check availability across their network often turns up stock that a single pharmacy search won’t reveal.
The underlying demand for GLP-1 medications shows no sign of slowing. Novo Nordisk’s massive capital investments are designed to keep pace over the next several years, but with new indications being studied and patient awareness continuing to grow, supply and demand will likely stay in tension for some time.